New CFO For Soligenix
Late-stage biopharma company Soligenix Inc. has appointed Karen Krumeich senior vice president and chief financial officer (CFO), following the retirement of current acting CFO Joseph Warusz at the end of this month. Prior to joining Soligenix, Krumeich served as a consultant providing finance, investor relations and business development services to the company, before which she was vice president and CFO for several development-stage life science companies, including Cerecor Inc. and Mela Sciences Inc.
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Diffusion Pharmaceuticals and WPD Pharmaceuticals get new chief medical officers.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.